SCHEMBL4746016

SCHEMBL4746016

Cc1ccc2c(c1)c(-c1cnc3ccccc3c1)cc1c3ccc(C)c4c3c(cc21)-c1ncccc1-4

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 5/20 0.37
ALDH1A1 P00352 2/20 0.37
BMPR1B O00238 1/20 0.37
PIK3C2G O75747 1/20 0.37
CDKL5 O76039 1/20 0.37
PIM1 P11309 1/20 0.37
TYK2 P29597 1/20 0.37
CLK2 P49760 1/20 0.37
DYRK1A Q13627 1/20 0.37
STK32B Q9NY57 1/20 0.37
PI4KB Q9UBF8 1/20 0.37
IRAK3 Q9Y616 1/20 0.37
CYP2A6 P11509 1/20 0.36
PDGFRB P09619 2/20 0.35
PDGFRA P16234 2/20 0.35
CYP1A2 P05177 1/20 0.35
PARP10 Q53GL7 1/20 0.35
PARP11 Q9NR21 1/20 0.35
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746018 0.90 ALDH1A1 (0.44) ALDH1A1DYRK1API4KBNPC1MAPT
SCHEMBL13320339 0.89 CYP1A2 (0.39) HSP90AA1ALDH1A1CYP2A6PDGFRBPDGFRA
SCHEMBL4745812 0.87 ALDH1A1 (0.34) ALDH1A1CYP2A6CYP1A2PIK3CASRC
SCHEMBL4746389 0.86 DHODH (0.34) ALDH1A1NPC1RAB9AABL1
SCHEMBL4746339 0.85 DHODH (0.36) ALDH1A1NPC1MAPTRAB9A
SCHEMBL4746387 0.85 DHODH (0.33) ALDH1A1NPC1RAB9A
SCHEMBL4746317 0.84 DHODH (0.35) ALDH1A1NPC1MAPTRAB9A
SCHEMBL4746019 0.84 ALDH1A1 (0.44) ALDH1A1CYP1A2
SCHEMBL4745849 0.83 CCR1 (0.35) ALDH1A1CYP1A2NPC1MAPTRAB9A
SCHEMBL4745792 0.83 BCHE (0.40) HSP90AA1ALDH1A1NPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 HSP90AA1 4527/4885ALDH1A1 179/4885BMPR1B 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.